MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently [...]
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview The DSMB, based on Phase 3 trial ARES preliminary data, concluded that MaaT013 has a favorable benefit/risk ratio with “high efficacy and low toxicity” in 3rd line aGvHD[1]. This evaluation confirms previous ones in a similar patient population from the EAP[2]. Primary endpoint ORR [...]
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently [...] 